# CheckMate 650 (NCT02985957)

> A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02985957
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Prostate Cancer
- Interventions: Nivolumab; Ipilimumab; Cabazitaxel; Prednisone
- Enrollment: 351
- Primary outcome: Objective Response Rate (ORR) Cohorts B and C Per BICR
- Primary outcome: Objective Response Rate (ORR) Cohort D
- Primary outcome: Radiographic Progression Free Survival (rPFS) for Cohorts B and C Per BICR
- Primary outcome: Radiographic Progression-Free Survival (rPFS) for Cohort D

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-650-nct02985957